Contact: +91-9711224068
  • Printed Journal
  • Indexed Journal
  • Refereed Journal
  • Peer Reviewed Journal
International Journal of Urology Research

Vol. 1, Issue 1, Part A (2019)

The effect of decreasing the dosage of finasteride in patients with benign prostatic hyperplasia: Our experience in a tertiary hospital

Author(s):

Krishna Rao SV, Preetam Penumatcha, Rambabu DVS

Abstract:

Background: Finasteride, a 5 alpha reductase inhibitor, is an established treatment for benign prostatic hyperplasia. The recommended dosage is 5 mg a day, however case reports have shown effectiveness with lower doses. The objective of the current study was to determine in men with benign prostatic hyperplasia, previously treated for at least one year with finasteride 5 mg daily, if they will maintain subjective and objective improvements in urinary obstruction when treated with 2.5 mg of finasteride daily for one year. Methods: In an open label, prospective study, 40 men with benign prostatic hyperplasia, previously treated for at least one year with 5 mg of finasteride, took 2.5 mg of finasteride daily for one year. Measurements included AUA symptom score, maximum flow rate, voided volume and PSA. Results: There were no significant changes in maximum flow rate, voided volume, or AUA symptom score after one year of finasteride 2.5 mg daily therapy. PSA increased significantly, p <. 01, after one year of finasteride 2.5 mg daily, 2.0 +1.4 ng/ml, when compared to finasteride 5 mg daily, 1.4+ 1.0 ng/ml. Conclusions: The daily dose of finasteride can be reduced to 2.5 mg daily without significant effect on subjective and objective measures of urinary obstruction. Although statistically significant increases in PSA are noted when reducing the daily finasteride dose from 5 mg to 2.5 mg, the clinical significance of a mean. 6 ng/ml increase in PSA is questionable.

Pages: 05-07  |  1128 Views  284 Downloads

How to cite this article:
Krishna Rao SV, Preetam Penumatcha, Rambabu DVS. The effect of decreasing the dosage of finasteride in patients with benign prostatic hyperplasia: Our experience in a tertiary hospital. Int. J. Urol. Res. 2019;1(1):05-07. DOI: 10.33545/26646617.2019.v1.i1a.2